Innoviva, Inc.
- Last sale
- Nov 12, 2026 · +0.61%
- Market cap
- $1.35B
- 71.08M shares
- Filings
- 1,014
Q3 2026+14.7% FY25 yoy
Q3 2026+1,059.2% FY25 yoy
Q3 2026−1.9% FY25 yoy
Q3 2026derived+3.9% FY25 yoy
Q3 2026+816.7% FY25 yoy
Q3 2026+80.7% FY25 yoy
- $1.35B
- 7.0×
- 3.1×
- 1.2×
- 13.53%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $411,328,000 | reported | |
| FY 2024 | 2024-12-31 | $358,711,000 | reported | |
| FY 2023 | 2023-12-31 | $310,463,000 | reported | |
| FY 2022 | 2022-12-31 | $331,339,000 | reported | |
| FY 2021 | 2021-12-31 | $391,866,000 | reported | |
| FY 2020 | 2020-12-31 | $336,794,000 | reported | |
| FY 2019 | 2019-12-31 | $261,016,000 | reported | |
| FY 2018 | 2018-12-31 | $261,004,000 | reported | |
| FY 2017 | 2017-12-31 | $217,217,000 | reported | |
| FY 2016 | 2016-12-31 | $133,569,000 | reported | |
| FY 2015 | 2015-12-31 | $53,949,000 | reported | |
| FY 2014 | 2014-12-31 | $8,433,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | — | $4.53M | $4.53M | — | 74.07M sh | +18.2% | 2.3% |
| FY2024 | — | $14.78M | $14.78M | — | 62.68M sh | −0.9% | 7.8% |
| FY2023 | — | $75.73M | $75.73M | — | 63.23M sh | −7.2% | 53.8% |
| FY2022 | — | $8.50M | $8.50M | — | 68.13M sh | −2.1% | 4.2% |
| FY2021 | $0.00 | $394.15M | $394.15M | — | 69.57M sh | −31.4% | 108.3% |
Segments
LineFY2025ShareChange
United States$77.38M100%+111.4%
Rest of the world———
Total$77.38M
Pharmaceutical preparations
Innoviva, Inc. is the 60th largest of the 552 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
NATRNatures Sunshine Products Inc$480.1M5.7%4.1%$178.3MZLABZai Lab Ltd$460.2M15.3%38.1%$29.3BARWRArrowhead Pharmaceuticals, Inc.$450.8M45.6%160.6%$6.7B
INVAInnoviva, Inc. (this company)$411.3M14.7%65.9%$1.3B
ARDXArdelyx, Inc.$407.3M22.1%15.1%$781.8MSVASinovac Biotech Ltd$386.0M6.8%51.5%$464.9MPHARPharming Group N.V.$376.1M26.6%0.8%$922.0MARQTArcutis Biotherapeutics, Inc.$376.1M91.3%4.3%$3.3BMNKDMannkind Corp$349.0M22.2%1.7%$1.3BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Innoviva, Inc. · CIK 1080014 · Engraved from SEC EDGAR